A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells

Breast Cancer Research and Treatment

Volumn 119, Issue 2, 2010, Pages 255-269

  Shuhendler, Adam J ^a   Cheung, Richard Y ^a   Manias, Janet ^a   Connor, Allegra ^a   Rauth, Andrew M ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Combination chemotherapy; Multidrug resistance; Polymer lipid hybrid nanoparticle

Indexed keywords

ANTHRACYCLINE; DOUBLE STRANDED DNA; DOXORUBICIN; MITOMYCIN C; NANOPARTICLE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENCAPSULATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMPOUNDING; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; KINETICS; MITOMYCIN; NANOPARTICLES; SOLUBILITY; TIME FACTORS;

EID: 74849110624     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0271-3     Document Type: Article

References (41)

1. Tannock IF, Goldenberg GJ (1998) Drug resistance and experimental chemotherapy. McGraw-Hill, Toronto
2. DN Waterhouse KA Gelmon, et al. 2006 Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers Curr Cancer Drug Targets 6 455 489 10.2174/156800906778194586 10.2174/156800906778194586 1:CAS:528: DC%2BD28Xos1Gqsb4%3D 17017873 (Pubitemid 44371970)
3. AU Buzdar 2006 Topoisomerase II alpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer J Clin Oncol 24 2409 2411 10.1200/JCO.2006.05.9113 10.1200/JCO.2006.05.9113 16682721 (Pubitemid 46630613)
4. Moore MJ, Erlichman C (2001) Pharmacology of anticancer drugs. In: Tannock IF, Hill RP (eds) The basic science of oncology. McGraw-Hill, Toronto, pp 370-391
5. P Pacini M Rinaldini, et al. 2000 FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results Eur J Cancer 36 966 975 10.1016/S0959-8049(00) 00068-X 10.1016/S0959-8049(00)00068-X 1:CAS:528:DC%2BD3cXjsVCqsL8%3D 10885599 (Pubitemid 30316420)
6. D Cameron R Bell, et al. 2006 What are the current standards of care and recent developments in the management of breast cancer? Oncologist 11 Suppl 1 1 3 10.1634/theoncologist.11-90001-1 10.1634/theoncologist.11-90001-1 16971733
7. HD Bear S Anderson, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 2019 2027 10.1200/JCO.2005.04.1665 10.1200/JCO.2005.04.1665 1:CAS:528:DC%2BD28Xlt1amur0%3D 16606972 (Pubitemid 46622110)
8. GW Sledge D Neuberg, et al. 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592 10.1200/JCO.2003.08.013 10.1200/JCO.2003.08.013 12586793 (Pubitemid 46621890)
9. E Salvatorelli P Menna, et al. 2006 Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies J Pharmacol Exp Ther 318 424 433 10.1124/jpet.106.103846 10.1124/jpet.106.103846 1:CAS:528:DC%2BD28XmsFymtbw%3D 16614166 (Pubitemid 43920784)
10. B Overmoyer 2003 Combination chemotherapy for metastatic breast cancer: reaching for the cure J Clin Oncol 21 580 582 10.1200/JCO.2003.10.085 10.1200/JCO.2003.10.085 12586790 (Pubitemid 46621887)
11. Y Xu CL Shapiro 2003 Rationale for mitomycin and irinotecan use in advanced breast cancer Oncology 17 25 28 1:CAS:528:DC%2BD3sXhvFGgtbw%3D 12800602 Williston Park
12. MA Villalona-Calero JM Kolesar 2002 Mitomycin as a modulator of irinotecan anticancer activity Oncology 16 21 25 12199629 Williston Park
13. A Bamias D Papamichael, et al. 2003 Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer J Chemother 15 275 281 1:CAS:528:DC%2BD3sXmtFSqurk%3D 12868555
14. HS Garewal 1988 Mitomycin C in the chemotherapy of advanced breast cancer Semin Oncol 15 74 79 1:STN:280:DyaL1c3nsl2hsw%3D%3D 3134698
15. RD Hofheinz U Beyer, et al. 2008 Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives Onkologie 31 271 281 10.1159/000122590 10.1159/000122590 1:CAS:528:DC%2BD1cXmtFGgtbk%3D 18497518 (Pubitemid 351744829)
16. SA Amiel JF Stewart, et al. 1984 Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer Eur J Cancer Clin Oncol 20 631 634 10.1016/0277-5379(84)90008-7 10.1016/0277-5379(84)90008-7 1:STN:280: DyaL2c3js1aqsA%3D%3D 6428893
17. M Andersson S Daugaard, et al. 1986 Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study Cancer Treat Rep 70 1181 1186 1:STN:280:DyaL2s%2Fgt1ansQ%3D%3D 3530444
18. RH Creech H Dayal RB Catalano 1984 Combination doxorubicin-mitomycin therapy for hormonal and CMF-refractory metastatic breast cancer Proc Am Soc Clin Oncol 3 126
19. MA Harris PJ Byrne, et al. 1984 Treatment of advanced breast cancer with two doxorubicin-containing regimens Am J Clin Oncol 7 51 58 10.1097/00000421- 198402000-00007 10.1097/00000421-198402000-00007 1:STN:280:DyaL2c7isFWqsA%3D%3D 6421145
20. RY Cheung AM Rauth, et al. 2006 In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin Eur J Pharm Biopharm 62 321 331 10.1016/j.ejpb.2005.09.011 10.1016/j.ejpb.2005.09.011 1:CAS:528:DC%2BD28Xit1Chu7s%3D 16330194 (Pubitemid 43356582)
21. RY Cheung AM Rauth XY Wu 2005 In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations Anticancer Drugs 16 423 433 10.1097/00001813-200504000- 00009 10.1097/00001813-200504000-00009 1:CAS:528:DC%2BD2MXhslyqsrw%3D 15746579 (Pubitemid 40434609)
22. AJ Shuhendler PJ O'Brien, et al. 2007 On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells Drug Metabol Drug Interact 22 201 234 1:CAS:528:DC%2BD1cXjtVyrtro%3D 18447000
23. AM Calcagno JM Fostel, et al. 2008 Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes Br J Cancer 98 1515 1524 10.1038/sj.bjc.6604334 1:CAS:528:DC%2BD1cXltl2it7g%3D 18382425 (Pubitemid 351652329)
24. T Fojo HM Coley 2007 The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies Clin Breast Cancer 7 749 756 10.3816/CBC.2007.n.035 10.3816/CBC.2007.n.035 1:CAS:528:DC%2BD2sXhsVeltbvE 18021475
25. A Hueber JM Esser, et al. 2008 Mitomycin C induces multidrug resistance in glaucoma surgery Graefes Arch Clin Exp Ophthalmol 246 297 304 10.1007/s00417-007-0695-1 10.1007/s00417-007-0695-1 1:CAS:528: DC%2BD1cXot1ymsw%3D%3D 17934748 (Pubitemid 351149636)
26. M Mimeault R Hauke SK Batra 2007 Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies Clin Pharmacol Ther 85 673 691
27. Z Liu JR Ballinger, et al. 2003 Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres J Pharm Pharmacol 55 1063 1073 10.1211/0022357021567 10.1211/0022357021567 1:CAS:528:DC%2BD3sXmvFGnsb0%3D 12956895 (Pubitemid 36998646)
28. Z Liu XY Wu R Bendayan 1999 In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells J Pharm Sci 88 412 418 10.1021/js9803353 10.1021/js9803353 1:CAS:528:DyaK1MXhslersLk%3D 10187751 (Pubitemid 29180765)
29. HL Wong R Bendayan, et al. 2004 Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers J Pharm Sci 93 1993 2008 10.1002/jps.20100 10.1002/jps.20100 1:CAS:528: DC%2BD2cXmvVKktL8%3D 15236449 (Pubitemid 39045481)
30. HL Wong R Bendayan, et al. 2006 Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer J Control Release 116 275 284 10.1016/j.jconrel.2006.09.007 10.1016/j.jconrel.2006.09.007 1:CAS:528: DC%2BD28Xht1KitL%2FM 17097178 (Pubitemid 44827405)
31. Y Li N Taulier, et al. 2006 Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN) Pharm Res 23 1877 1887 10.1007/s11095-006-9033-2 10.1007/s11095-006-9033-2 1:CAS:528: DC%2BD28XnvVymtr4%3D 16850265 (Pubitemid 44200552)
32. HL Wong R Bendayan, et al. 2006 A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J Pharmacol Exp Ther 317 1372 1381 10.1124/jpet.106.101154 10.1124/jpet.106.101154 1:CAS:528: DC%2BD28Xlt1equ78%3D 16547167 (Pubitemid 43764144)
33. HL Wong AM Rauth, et al. 2006 A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells Pharm Res 23 1574 1585 10.1007/s11095-006-0282-x 10.1007/s11095-006-0282-x 1:CAS:528:DC%2BD28XmsFOmu7o%3D 16786442 (Pubitemid 43993820)
34. HL Wong AM Rauth, et al. 2007 In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model Eur J Pharm Biopharm 65 300 308 10.1016/j.ejpb.2006.10.022 10.1016/j.ejpb.2006.10.022 1:CAS:528:DC%2BD2sXisVCgsL4%3D 17156986 (Pubitemid 46320248)
35. Bristow RG, Hill RP (1998) Molecular and cellular basis of radiotherapy. McGraw-Hill, Toronto
36. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 621 681 10.1124/pr.58.3.10 10.1124/pr.58.3.10 1:CAS:528:DC%2BD28XhtVOhtLfL 16968952 (Pubitemid 44403686)
37. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 10.1016/0065-2571(84)90007-4 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D 6382953
38. E Devarajan J Chen, et al. 2002 Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features Int J Oncol 20 913 920 1:CAS:528:DC%2BD38XktVSmt7s%3D 11956583
39. Y Noguchi J Wu, et al. 1998 Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn J Cancer Res 89 307 314 1:CAS:528:DyaK1cXis1arsbY%3D 9600125
40. RH Muller K Mader S Gohla 2000 Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur J Pharm Biopharm 50 161 177 10.1016/S0939-6411(00)00087-4 10.1016/S0939-6411(00)00087-4 1:CAS:528:DC%2BD3cXjslyisrg%3D 10840199 (Pubitemid 30326695)
41. M Tanner P Jarvinen J Isola 2001 Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer Cancer Res 61 5345 5348 1:CAS:528:DC%2BD3MXlsVChsrw%3D 11454672